Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment
Authors: Callari Maurizio , Barreca Marco , Dugo Matteo , Galbardi Barbara , Viganò Lucia , Locatelli Alberta , Licata Luca , Viale Giulia , Valagussa Pinuccia , Viale Giuseppe , Gianni Luca , Bianchini Giampaolo 
Published: March 2022

Abstract
Background - Chemotherapy is the current backbone of immune checkpoint inhibitors (ICIs) for approved indications in triple negative breast cancer (TNBC). While it is expected that different chemotherapeutic agents might have distinct immunomodulatory effects, data in patients is scarce. Here we compared the early modulation of molecular pathways and immune-related features in TNBC patients receiving neoadjuvant doxorubicin/cyclophosphamide (AC) or nab-paclitaxel/carboplatin (nab/C). Methods - Two cohorts of TNBC patients with available RNA-seq for paired core biopsies obtained before (baseline) and after the first cycle of neoadjuvant chemotherapy (day 21, D1C2) were selected: i) 84 patients treated with nab/C from the control arm of the NeoTRIPaPDL1 trial (Gianni L SABCS 2019, Bianchini G ESMO 2021); ii) 22 patients treated with AC from a publicly available dataset (Park Nat Comms 2020). Presence of immune cell populations was estimated by gene expression profile deconvolution using ConsensusTME R package (n=19). Hallmark gene set collection and custom signature activation status were estimated in each sample using singscore R package (n=63). We also assessed modulation of PD-L1 gene expression and selected immune-related genes. To minimize batch effects between the two cohorts, in each dataset, median score expression at baseline was subtracted from all samples. Continuous scores were compared by 2-sided t-test. Results - Thirty-nine pathways were significantly and similarly modulated in both cohorts (all p&lt;0.01) at D1C2 compared to baseline. They included upregulation of all immune cell related signatures (e.g. T cells, dendritic cells, monocytes and macrophages, B cells and NK), immune function-related signatures and apoptosis, and downregulation of proliferation related signatures. PD-L1 gene expression was upregulated in both cohorts (p&lt;0.001). A comparison between D1C2 of the two cohorts was performed to evaluate whether chemotherapies differently modulated gene signatures. Nab/C more strongly downregulated signatures of G2M checkpoint, mitotic spindle, DNA repair, MYC targets and oxidative phosphorylation. AC more strongly upregulated some immune-related signatures (e.g. cytotoxic cells, CD4+ T-cells, regulatory T cells, IL2/STAT5 and JAK/STAT3) and apoptosis. PD-L1 was more upregulated in AC cohort (p=0.006). For each signature, we identified, in each cohort, patients ‘signature high’ and ‘signature low’ using the median value at baseline as a threshold. We then investigated whether signature modulation at D1C2 was different in the two groups. In ‘signature high’ patients, immune-related signatures were similarly upregulated, whereas nab/C showed downregulation of proliferation related markers. In ‘signature low’ patients, a more robust upregulation of all immune-related signatures was observed in both cohorts (all p&lt;0.0001), but it was quantitatively stronger in AC arm for several immune signatures (e.g. cytotoxic cells, gamma/delta T cells, CD4+ T-cells, regulatory T cells, NK) (p&lt;0.01). PD-L1 was significantly upregulated at D1C2 only in PD-L1 low group in both cohorts (p&lt;0.0001), but the effect was stronger in AC (p=0.014). Chemotherapy induced modulation of other individual genes will be presented at the meeting. Conclusions - The two investigated chemotherapy regimens had a strong early immunomodulatory and chemoattractant effect, which confirms the rationale for combination with ICIs. Anthracyclines elicit a quantitatively stronger immune modulatory effect compared to nab/C, which is particularly evident in. “immune low” tumors. These observations can have clinical implications for the selection of the ideal chemotherapy partner to ICIs in not-inflamed/PD-L1 negative tumors.
Citation Format: Maurizio Callari, Marco Barreca, Matteo Dugo, Barbara Galbardi, Lucia Viganò, Alberta Locatelli, Luca Licata, Giulia Viale, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini. Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD10-09.